csp

Competence-Stimulating Peptide-2 (CSP-2) is a quorum sensing signal peptide synthesized by Streptococcus pneumoniae. Its compatible receptor, ComD2, exhibits an EC50 value of 50.7 nM.

CSP1 is a highly potent and selective agonist of the ComD1 receptor, exhibiting an IC50 value of 10.3 nM. It represents a major variant of competence-stimulating peptide (CSP) and plays a crucial role in regulating the genetic transformation of S. pneumoniae through modulation of quorum sensing (QS). Additionally, CSP1 possesses antibacterial activity, further enhancing its potential as an effective antibacterial agent.

CSP-2503 is a 5-HT1A receptor agonist.

TTK21 is an activator of CBP/p300 histone acetyltransferase activity.

Itanapraced (CHF5074), a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).

cSPM (Cyclic spermine) is an Aβ42 inhibitor. cSPM inhibits the aggregation of three different peptides, Aβ42, tryptophan and insulin, and reduces cytotoxicity.

CSPD substrate is a chemiluminescent substrate for alkaline phosphatase. It offers increased sensitivity for alkaline phosphatase detection and simplifies the assay process.

TCS PrP Inhibitor 13 (5-(4-Nitrophenyl)-2-Phenyl-4H-Pyrazol-3-One) is an antiprion agent inhibiting protease-resistant prion protein (PrP-res) accumulation.

3-Cl-DPA, a cardiac troponin activator, acts by a mechanism distinct from bepridil or TFP.

DMAC-SPP is a cleavable linker vital in ADC synthesis. DMAC-SPP joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

PC SPDP-NHS carbonate ester is a cleavable linker compound used in the synthesis of antibody-drug conjugates (ADCs) [1].

Sulfo-DMAC-SPP is an ADC linker employed for the synthesis of antibody-drug conjugates (ADCs) [1].

Sulfo-LC-SPDP is a heterobifunctional crosslinker characterized by its thiol-cleavable and membrane impermeable properties.

(Rac)-Spirotetramat-enol (Compound 8) serves as a ligand for target proteins, utilized in the synthesis of PROTAC ACC degrader.

TC-SP 14, also known as compound 14, is a highly active and potent S1P1 agonist with oral bioavailability. It exhibits an EC50 value of 0.042 μM, indicating its strong binding affinity to the S1P1 receptor. Notably, its interaction with the S1P3 receptor is minimal, as evidenced by an EC50 value of 3.47 μM. TC-SP 14 demonstrates significant pharmacological effects, including a marked reduction in blood lymphocyte counts and the attenuation of delayed type hypersensitivity response to antigen challenge [1].

TCS PIM-1 1 (SC 204330)(sc-204330) is an effective and specific ATP-competitive Pim-1 kinase inhibitor (IC50: 50 nM), exhibiting good specificity over MEK1/MEK2 and Pim-2 (IC50s > 20,000 nM).

induces phenotypic differentiation

GSK329 is an effective and selective inhibitor of TNNI3 Interacting Kinase (TNNI3K). GSK329 exhibits positive cardioprotective outcomes in the model of ischemia/reperfusion cardiac injury.

KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.

(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.

DMAC-SPDB is a cleavable linker vital in ADC synthesis. DMAC-SPDB joins cytotoxic drugs to antibodies, enabling precise delivery to cells or proteins. The cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

DMAC-SPDB-sulfo is a cleavable linker essential in ADC synthesis, enabling precise delivery of cytotoxic drugs to cells or proteins by attaching them to antibodies. Its cleavable nature ensures controlled drug release, optimizing ADC effectiveness.

TCS-PIM-1-4a (SMI-4a), a Pim inhibitor, blocks mTORC1 activity through activation of AMPK and kills a wide range of both myeloid and lymphoid cell lines (IC50=0.8-40 μM).

MC-VC-PABC-SP 141 is a potent antitumor conjugate for antibody-drug conjugation (ADC), featuring SP 141, a robust MDM2 inhibitor, connected through the cleavable linker [MC-VC-PABC], facilitating targeted cancer therapy.